Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H.
Winthrop KL, et al.
Ann Rheum Dis. 2016 Jun;75(6):1133-8. doi: 10.1136/annrheumdis-2015-207319. Epub 2015 Aug 28.
Ann Rheum Dis. 2016.
PMID: 26318385
Free PMC article.
Review.
TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks (range 15-161 weeks). ...CONCLUSIONS: Within the global tofacitinib RA development programme, TB was the most common OI reported but …
TB (crude IR 0.21, 95% CI of (0.14 to 0.30)) was the most common OI (n=26); median time between drug start and diagnosis was 64 weeks …